Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 6/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361309 | 0.88 | NPSR1 (0.45) | NPSR1KDM4EALDH1A1SIRT6ATR | |
| SCHEMBL4253183 | 0.86 | SIRT6 (0.47) | KDM4EALDH1A1SIRT6ATRKCNH2 | |
| SCHEMBL30050535 | 0.84 | ATR (0.54) | NPSR1KDM4EALDH1A1ATRPKM | |
| SCHEMBL261742 | 0.84 | ATR (0.54) | NPSR1KDM4EALDH1A1ATRPKM | |
| SCHEMBL29277699 | 0.83 | NPSR1 (0.41) | NPSR1KDM4EALDH1A1ATRPKM | |
| SCHEMBL31214137 | 0.82 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1SIRT6MAPK1 | |
| SCHEMBL19718220 | 0.81 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1ATRPKM | |
| SCHEMBL27731674 | 0.81 | NPSR1 (0.45) | NPSR1KDM4EALDH1A1SIRT6MAPK1 | |
| SCHEMBL262307 | 0.80 | GRM5 (0.54) | NPSR1KDM4EALDH1A1ATRPKM | |
| SCHEMBL7449256 | 0.80 | L3MBTL1 (0.41) | NPSR1KDM4EMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | claimed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | claimed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | claimed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | claimed |
| EP-2580207-B1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-8703768-B2 | Nitrogen containing heteroaryl compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8623866-B2 | — | — | 2014-01-07 | — | — | US | disclosed |
| EP-2580207-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154327-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | ASTRAZENECA AB (SE) | 2009-07-16 | — | — | US | disclosed |
| CN-101336238-A | Novel bicyclic carbonylaminopyridine-2-carboxamides or 3-bicyclic carbonylaminopyrazine-2-carboxamides | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | CN | disclosed |
| EP-1957478-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061360-A2 | NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181968-A1 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 | NPSR1 1379/4885KDM4E 1638/4885ALDH1A1 542/4885 |
| US-20110306589-A1 | NITROGEN CONTAINING HETEROARYL COMPOUNDS | PDE10A, PDE3A, PDE2A | NPSR1 148/4885KDM4E 2322/4885ALDH1A1 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.